Dashboard
Manage Tickers

RAREUltragenyx Pharmaceutical Inc.

Nasdaq ultragenyx.com


$ 55.71 $ -1.07 (-1.88 %)    

Tuesday, 03-Sep-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 459.18 $ 0.09 (0.02 %)
DIA $ 410.26 $ -5.96 (-1.43 %)
SPY $ 551.70 $ -11.60 (-2.06 %)
TLT $ 97.57 $ 1.26 (1.31 %)
GLD $ 230.29 $ -1.00 (-0.43 %)
$ 55.71
$ 55.66 x 100
-- x --
-- - --
$ 31.52 - $ 58.73
694,414
na
5.13B
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-21-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 02-17-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 07-28-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-15-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 02-12-2021 12-31-2020 10-K
16 10-27-2020 09-30-2020 10-Q
17 07-31-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-14-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-02-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-20-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 02-21-2018 12-31-2017 10-K
28 11-03-2017 09-30-2017 10-Q
29 07-28-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 02-17-2017 12-31-2016 10-K
32 11-08-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 02-26-2016 12-31-2015 10-K
36 11-10-2015 09-30-2015 10-Q
37 08-14-2015 06-30-2015 10-Q
38 05-12-2015 03-31-2015 10-Q
39 03-27-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

novartis-and-viatris-sued-over-unlawful-use-of-hela-cells-used-for-cancer-treatment-drugs
Novartis And Viatris Sued Over Unlawful Us...
08/06/2024 17:48:49

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks prof...

barclays-maintains-overweight-on-ultragenyx-pharmaceutical-lowers-price-target-to-81
Barclays Maintains Overweight on Ultrageny...
08/05/2024 23:01:04

Barclays analyst Gena Wang maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target f...

goldman-sachs-maintains-buy-on-ultragenyx-pharmaceutical-raises-price-target-to-76
Goldman Sachs Maintains Buy on Ultragenyx ...
08/02/2024 16:59:15

Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price targ...

cantor-fitzgerald-maintains-overweight-on-ultragenyx-pharmaceutical-raises-price-target-to-116
Cantor Fitzgerald Maintains Overweight on ...
08/02/2024 15:07:57

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the ...

wedbush-maintains-neutral-on-ultragenyx-pharmaceutical-raises-price-target-to-46
Wedbush Maintains Neutral on Ultragenyx Ph...
08/02/2024 13:09:45

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and raises the price target fro...

ultragenyx-pharmaceutical-raises-fy24-revenue-guidance-from-500m-530m-to-530m-550m-vs-51316m-est
Ultragenyx Pharmaceutical Raises FY24 Reve...
08/01/2024 20:27:39

2024 Full Year Financial GuidanceTotal revenue guidance increased to be in the range of $530 million to $550 million (previousl...

ultragenyx-pharmaceutical-q2-eps-152-beats-172-estimate-sales-14703m-beat-12318m-estimate
Ultragenyx Pharmaceutical Q2 EPS $(1.52) B...
08/01/2024 20:26:56

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimat...

ultragenyx-to-present-gtx-102-angelman-syndrome-program-update-at-the-asf-family-conference-and-research-symposium-on-wednesday-july-24-2024
Ultragenyx To Present GTX-102 Angelman Syn...
07/24/2024 12:09:57

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the company will share the latest clinical data, regulatory p...

canaccord-genuity-maintains-buy-on-ultragenyx-pharmaceutical-maintains-111-price-target
Canaccord Genuity Maintains Buy on Ultrage...
07/23/2024 11:41:30

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and maintains $111 price...

ionis-rare-development-disorder-drug-candidate-could-be-differentiated-from-peer-ultragenyx-analyst
Ionis' Rare Development Disorder Drug Cand...
07/22/2024 17:04:26

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinic...

unveiling-14-analyst-insights-on-ultragenyx-pharmaceutical
Unveiling 14 Analyst Insights On Ultrageny...
07/22/2024 16:01:19

cantor-fitzgerald-reiterates-overweight-on-ultragenyx-pharmaceutical-maintains-115-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/22/2024 15:42:52

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains ...

wedbush-reiterates-neutral-on-ultragenyx-pharmaceutical-maintains-45-price-target
Wedbush Reiterates Neutral on Ultragenyx P...
07/18/2024 13:45:09

Wedbush analyst Laura Chico reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and maintains $45 price target.

ultragenyx-aligns-with-fda-on-phase-3-study-endpoints-for-gtx-102-phase-3-study-to-initiate-by-year-end-successful-end-of-phase-2-meeting-supports-plans-for-global-double-blind-sham-controlled-pivotal-study-additional-study-planned-for-patients-with-other-mutations
Ultragenyx Aligns With FDA On Phase 3 Stud...
07/17/2024 20:06:47

Core News & Articles
'Biogen Is Pursuing More Dealmaking This Y...
06/27/2024 15:39:59

https://endpts.com/biogen-is-pursuing-more-dealmaking-this-year-with-plans-to-spend-up-to-8B/  

why-ammo-shares-are-trading-lower-by-over-19-here-are-other-stocks-moving-in-fridays-mid-day-session
Why AMMO Shares Are Trading Lower By Over ...
06/14/2024 18:13:08

reported-earlier-ultragenyx-prices-350m-public-offering-of-7435898-common-shares-at-39share-and-pre-funded-warrants
Reported Earlier, Ultragenyx Prices $350M ...
06/14/2024 06:27:39

In addition, in lieu of issuing common stock to certain investors, the company is offering pre-funded warrants to purchase 1,53...

dave--busters-posts-downbeat-results-joins-jjill-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Dave & Buster's Posts Downbeat Results, Jo...
06/13/2024 09:51:52

ultragenyx-pharmaceutical-commences-350m-public-offering-of-common-stock-and-pre-funded-warrants
Ultragenyx Pharmaceutical Commences $350M ...
06/12/2024 20:07:39

ultragenyx-plans-to-file-for-accelerated-approval-of-ux111-for-the-treatment-of-sanfilippo-syndrome-type-a-after-meeting-with-fda
Ultragenyx Plans To File For Accelerated A...
06/12/2024 20:00:59

Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION